Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 12
2006 15
2007 8
2008 11
2009 6
2010 5
2011 5
2012 11
2013 12
2014 17
2015 8
2016 5
2017 7
2018 4
2019 14
2020 28
2021 34
2022 30
2023 28
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Results by year

Filters applied: . Clear all
Page 1
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, Rizvi N, Gao B, Li S, Lee S, McGuire K, Chen CI, Makharadze T, Paydas S, Nechaeva M, Seebach F, Weinreich DM, Yancopoulos GD, Gullo G, Lowy I, Rietschel P. Sezer A, et al. Among authors: kilickap s. Lancet. 2021 Feb 13;397(10274):592-604. doi: 10.1016/S0140-6736(21)00228-2. Lancet. 2021. PMID: 33581821 Clinical Trial.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M, Kilickap S, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Ho GF, Kulyaba Y, Zyuhal K, Scheusan RI, Garassino MC, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Özgüroğlu M, et al. Among authors: kilickap s. Lancet Oncol. 2023 Sep;24(9):989-1001. doi: 10.1016/S1470-2045(23)00329-7. Epub 2023 Aug 14. Lancet Oncol. 2023. PMID: 37591293 Clinical Trial.
Lung Cancer in Turkey.
Cangır AK, Yumuk PF, Sak SD, Akyürek S, Eralp Y, Yılmaz Ü, Selek U, Eroğlu A, Tatlı AM, Dinçbaş FÖ, Kılıçkap S, Şendur MAN, Dilektaşlı AG, Bozcuk HŞ, Özkök S, Öztop İ, Topkan E, Dilege Ş, Kaya A, Demirkazık A; Turk Oncology Group. Cangır AK, et al. Among authors: kilickap s. J Thorac Oncol. 2022 Oct;17(10):1158-1170. doi: 10.1016/j.jtho.2022.06.001. J Thorac Oncol. 2022. PMID: 36192076 Free article. No abstract available.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Gümüş M, Chen CI, Ivanescu C, Kilickap S, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Harnett J, Mastey V, Naumann U, Reaney M, Konidaris G, Sasane M, Brady KJS, Li S, Gullo G, Rietschel P, Sezer A. Gümüş M, et al. Among authors: kilickap s. Cancer. 2023 Jan 1;129(1):118-129. doi: 10.1002/cncr.34477. Epub 2022 Oct 29. Cancer. 2023. PMID: 36308296 Free PMC article. Clinical Trial.
Endpoints in oncology clinical trials.
Kilickap S, Demirci U, Karadurmus N, Dogan M, Akinci B, Sendur MAN. Kilickap S, et al. J BUON. 2018 Dec;23(7):1-6. J BUON. 2018. PMID: 30722104 Free article. Review.
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, Wu L, Wang X, Viguro M, Makharadze T, Sun H, Luo F, Shi J, Zang A, Pan Y, Chen Z, Jia Z, Kuchava V, Lu P, Zhang L, Cheng Y, Kang W, Wang Q, Yu H, Li J, Zhu J; ASTRUM-004 Investigators. Zhou C, et al. Among authors: kilickap s. Cancer Cell. 2024 Feb 12;42(2):198-208.e3. doi: 10.1016/j.ccell.2023.12.004. Epub 2024 Jan 4. Cancer Cell. 2024. PMID: 38181795 Clinical Trial.
Thirty-day mortality rates after immunotherapy initiation.
Sütcüoğlu O, İlhan A, Tacar SY, Güven DC, Uçar G, Karadurmuş N, Yıldız F, Eraslan E, Uncu D, Tural D, Üner A, Günel N, Özdemir N, Kılıçkap S, Öksüzoğlu ÖB, Özet A, Yazıcı O. Sütcüoğlu O, et al. Among authors: kilickap s. Immunotherapy. 2021 Dec;13(17):1419-1426. doi: 10.2217/imt-2021-0082. Epub 2021 Oct 22. Immunotherapy. 2021. PMID: 34676791
232 results